Scientists can now design genetic material called mRNA to help us build immunity to certain viruses, including SARS-CoV-2, ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations were $-2.92. Operator: Good day, and thank you for standing by. Welcome to ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% ...

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and ...

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

NIH program to make vaccines against pathogens that can trigger pandemics uses approach pioneered in last century ...

Banning mRNA technology in response to the many missteps of public health officials during the pandemic is a textbook example ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, ...